These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 11485353

  • 1. 4-1BBL enhances anti-tumor responses in the presence or absence of CD28 but CD28 is required for protective immunity against parental tumors.
    Guinn BA, Bertram EM, DeBenedette MA, Berinstein NL, Watts TH.
    Cell Immunol; 2001 May 25; 210(1):56-65. PubMed ID: 11485353
    [Abstract] [Full Text] [Related]

  • 2. 4-1BBL cooperates with B7-1 and B7-2 in converting a B cell lymphoma cell line into a long-lasting antitumor vaccine.
    Guinn BA, DeBenedette MA, Watts TH, Berinstein NL.
    J Immunol; 1999 Apr 15; 162(8):5003-10. PubMed ID: 10202049
    [Abstract] [Full Text] [Related]

  • 3. Analysis of 4-1BB ligand (4-1BBL)-deficient mice and of mice lacking both 4-1BBL and CD28 reveals a role for 4-1BBL in skin allograft rejection and in the cytotoxic T cell response to influenza virus.
    DeBenedette MA, Wen T, Bachmann MF, Ohashi PS, Barber BH, Stocking KL, Peschon JJ, Watts TH.
    J Immunol; 1999 Nov 01; 163(9):4833-41. PubMed ID: 10528184
    [Abstract] [Full Text] [Related]

  • 4. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors.
    Hiraoka S, Takeuchi N, Bian Y, Nakahara H, Kogo M, Dunussi-Joannopoulos K, Wolf S, Ono S, Fujiwara H.
    Int Immunol; 2005 Aug 01; 17(8):1071-9. PubMed ID: 16027141
    [Abstract] [Full Text] [Related]

  • 5. Tumor cells cotransfected with interleukin-7 and B7.1 genes induce CD25 and CD28 on tumor-infiltrating T lymphocytes and are strong vaccines.
    Cayeux S, Beck C, Aicher A, Dörken B, Blankenstein T.
    Eur J Immunol; 1995 Aug 01; 25(8):2325-31. PubMed ID: 7545119
    [Abstract] [Full Text] [Related]

  • 6. Role of IL-12 and 4-1BB ligand in cytokine production by CD28+ and CD28- T cells.
    Chu NR, DeBenedette MA, Stiernholm BJ, Barber BH, Watts TH.
    J Immunol; 1997 Apr 01; 158(7):3081-9. PubMed ID: 9120260
    [Abstract] [Full Text] [Related]

  • 7. Costimulation of CD28- T lymphocytes by 4-1BB ligand.
    DeBenedette MA, Shahinian A, Mak TW, Watts TH.
    J Immunol; 1997 Jan 15; 158(2):551-9. PubMed ID: 8992967
    [Abstract] [Full Text] [Related]

  • 8. Heterogeneous effects of B7-1 and B7-2 in the induction of both protective and therapeutic anti-tumor immunity against different mouse tumors.
    Martin-Fontecha A, Cavallo F, Bellone M, Heltai S, Iezzi G, Tornaghi P, Nabavi N, Forni G, Dellabona P, Casorati G.
    Eur J Immunol; 1996 Aug 15; 26(8):1851-9. PubMed ID: 8765031
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. 4-1BB ligand, a member of the TNF family, is important for the generation of antiviral CD8 T cell responses.
    Tan JT, Whitmire JK, Ahmed R, Pearson TC, Larsen CP.
    J Immunol; 1999 Nov 01; 163(9):4859-68. PubMed ID: 10528187
    [Abstract] [Full Text] [Related]

  • 11. Triggering of murine NK cells by CD40 and CD86 (B7-2).
    Martín-Fontecha A, Assarsson E, Carbone E, Kärre K, Ljunggren HG.
    J Immunol; 1999 May 15; 162(10):5910-6. PubMed ID: 10229827
    [Abstract] [Full Text] [Related]

  • 12. The capacity of the natural ligands for CD28 to drive IL-4 expression in naïve and antigen-primed CD4+ and CD8+ T cells.
    Bian Y, Hiraoka S, Tomura M, Zhou XY, Yashiro-Ohtani Y, Mori Y, Shimizu J, Ono S, Dunussi-Joannopoulos K, Wolf S, Fujiwara H.
    Int Immunol; 2005 Jan 15; 17(1):73-83. PubMed ID: 15569772
    [Abstract] [Full Text] [Related]

  • 13. CD28 is not required for rejection of unmanipulated syngeneic and autologous tumors.
    Wen T, Kono K, Shahinian A, Kiessling R, Mak TW, Klein G.
    Eur J Immunol; 1997 Aug 15; 27(8):1988-93. PubMed ID: 9295036
    [Abstract] [Full Text] [Related]

  • 14. Cytokine gene therapy of gliomas: induction of reactive CD4+ T cells by interleukin-4-transfected 9L gliosarcoma is essential for protective immunity.
    Giezeman-Smits KM, Okada H, Brissette-Storkus CS, Villa LA, Attanucci J, Lotze MT, Pollack IF, Bozik ME, Chambers WH.
    Cancer Res; 2000 May 01; 60(9):2449-57. PubMed ID: 10811123
    [Abstract] [Full Text] [Related]

  • 15. Requirements for CD28-dependent T cell-mediated cytotoxicity.
    Azuma M, Cayabyab M, Phillips JH, Lanier LL.
    J Immunol; 1993 Mar 15; 150(6):2091-101. PubMed ID: 8383716
    [Abstract] [Full Text] [Related]

  • 16. B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.
    Lu ZY, Condomines M, Tarte K, Nadal L, Delteil MC, Rossi JF, Ferrand C, Klein B.
    Exp Hematol; 2007 Mar 15; 35(3):443-53. PubMed ID: 17309825
    [Abstract] [Full Text] [Related]

  • 17. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen.
    Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R.
    J Immunol; 2003 Mar 15; 170(6):2912-22. PubMed ID: 12626542
    [Abstract] [Full Text] [Related]

  • 18. Contribution of the CD28 molecule to allergic and irritant-induced skin reactions in CD28 -/- mice.
    Kondo S, Kooshesh F, Wang B, Fujisawa H, Sauder DN.
    J Immunol; 1996 Dec 01; 157(11):4822-9. PubMed ID: 8943384
    [Abstract] [Full Text] [Related]

  • 19. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
    Xu DP, Sauter BV, Huang TG, Meseck M, Woo SL, Chen SH.
    Gene Ther; 2005 Oct 01; 12(20):1526-33. PubMed ID: 15973445
    [Abstract] [Full Text] [Related]

  • 20. Protective immunity induced by B7/CD28-costimulated gamma delta T cells to the EL-4 lymphoma in allogenic athymic mice.
    Li Y, Newby SA, Johnston JV, Hellström KE, Chen L.
    J Immunol; 1995 Dec 15; 155(12):5705-10. PubMed ID: 7499857
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.